Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13246726 | 0.94 | L3MBTL1 (0.50) | L3MBTL1NPC1RAB9ALMNAMAPT | |
| SCHEMBL18751674 | 0.89 | CES1 (0.46) | L3MBTL1LMNAALDH1A1HPGDMAPK1 | |
| SCHEMBL16722805 | 0.83 | ELANE (0.52) | L3MBTL1LMNAALDH1A1KMT2AHPGD | |
| SCHEMBL18116111 | 0.81 | CA2 (0.56) | LMNAMAPTALDH1A1POLBHPGD | |
| SCHEMBL11389533 | 0.81 | HPGD (0.55) | L3MBTL1NPC1RAB9ALMNAALDH1A1 | |
| SCHEMBL8980228 | 0.81 | CA2 (0.56) | NPC1RAB9ALMNACTBP2MAPK1 | |
| SCHEMBL454778 | 0.80 | PLAAT3 (0.51) | L3MBTL1ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL11131275 | 0.80 | L3MBTL1 (0.51) | L3MBTL1NPC1RAB9ALMNAMAPT | |
| SCHEMBL12895730 | 0.80 | CNR2 (0.46) | L3MBTL1NPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL18116103 | 0.79 | EPHX2 (0.44) | LMNAALDH1A1HPGDCNR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915264-B2 | Drugs for treating pain formed by arylation | NOVARTIS AG (CH) | 2011-03-29 | — | — | US | claimed |
| US-20040138454-A1 | Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain | CULSHAW ANDREW JAMES (GB) | 2004-07-15 | — | — | US | claimed |
| CN-1500089-A | Fused pyridine derivatives as capsaicin receptor antagonists for the treatment of pain | ��˹��ŵ�� | 2004-05-26 | — | — | CN | claimed |
| EP-1377576-A2 | PYRIDINE DERIVATIVES | Novartis AG (CH) | 2004-01-07 | — | — | EP | claimed |
| WO-2002076946-A2 | FUSED PYRIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR ANTAGONISTS FOR TREATING PAIN. | NOVARTIS AG (CH) | 2002-10-03 | — | — | WO | claimed |
| US-20230041563-A1 | N-(1,3,4-OXADIAZOL-2-YL)ARYLCARBOXAMIDES OR SALTS THEREOF, PREPARATION METHODS, HERBICIDAL COMPOSITIONS AND USES THEREOF | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| US-20220400678-A1 | OXIME ETHER COMPOUND AND APPLICATION THEREOF | SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD. (CN) | 2022-12-22 | — | — | US | disclosed |
| WO-2016167361-A1 | METHOD FOR PRODUCING ORGANIC COMPOUND SUBSTANTIALLY FREE OF Pd, AND NOVEL METHOD FOR REMOVING Pd FROM ORGANIC COMPOUND USING HYDROGEN GAS | アステラス製薬株式会社 | 2016-10-20 | — | — | WO | disclosed |
| US-8486370-B2 | Heterocyclic ligands for integrin imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-16 | — | — | US | disclosed |
| US-7915264-B2 | Drugs for treating pain formed by arylation | NOVARTIS AG (CH) | 2011-03-29 | — | — | US | disclosed |
| US-20100317621-A1 | BETA-LACTAMASE INHIBITORS | PROTEZ PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-12-09 | — | — | US | disclosed |
| US-7576175-B2 | Amino acid terminated diphenylurea derivatives; display high binding affinity, specificity, and stability; use in treating cancer, inflammatory diseases, and autoimmune diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-08-18 | — | — | US | disclosed |
| US-7342016-B2 | Farnesyl protein transferase inhibitors as antitumor agents | SCHERING CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | US | disclosed |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | US | disclosed |
| US-20040138454-A1 | Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain | CULSHAW ANDREW JAMES (GB) | 2004-07-15 | — | — | US | disclosed |
| CN-1500089-A | Fused pyridine derivatives as capsaicin receptor antagonists for the treatment of pain | ��˹��ŵ�� | 2004-05-26 | — | — | CN | disclosed |
| EP-1377576-A2 | PYRIDINE DERIVATIVES | Novartis AG (CH) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002076946-A2 | FUSED PYRIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR ANTAGONISTS FOR TREATING PAIN. | NOVARTIS AG (CH) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | ITGA1, ITGAL, ITGA4 | L3MBTL1 748/4885NPC1 3565/4885RAB9A 1592/4885 |
| US-20100317621-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | L3MBTL1 1425/4885NPC1 2957/4885RAB9A 458/4885 |
| US-20230041563-A1 | N-(1,3,4-OXADIAZOL-2-YL)ARYLCARBOXAMIDES OR SALTS THEREOF, PREPARATION METHODS, HERBICIDAL COMPOSITIONS AND USES THEREOF | CYP2B6, CBR3, CYP2A6 | L3MBTL1 1742/4885NPC1 2545/4885RAB9A 3975/4885 |
| US-20040138454-A1 | Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain | TRPV1, OPRL1, OPRK1 | L3MBTL1 4241/4885NPC1 1903/4885RAB9A 1330/4885 |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | ITGA4, ITGB4, ITGA1 | L3MBTL1 650/4885NPC1 2481/4885RAB9A 2130/4885 |
| US-20220400678-A1 | OXIME ETHER COMPOUND AND APPLICATION THEREOF | CYP2E1, GALE, OGFOD1 | L3MBTL1 3034/4885NPC1 3686/4885RAB9A 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.